← Back to all trials
Completed
NCT07264335
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
Conditions: Atopic Dermatitis
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 160
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Location: The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui
Summary
This study is a randomized, parallel-group, open-label Phase I clinical trial designed to compare the bioavailability and safety of subcutaneous SHR-1819 injection administered via different injection devices in healthy subjects.
Eligibility Criteria
Inclusion Criteria:
1. Understanding the research procedures and methods, being able to complete the research in accordance with the procedure requirements, and sign the informed consent;
2. The age on the date of signing the informed consent must be ≥18 years old and ≤55 years old;
3. Body mass index (BMI) at screening period must be ≥19.0 kg/m2 and \
Source: ClinicalTrials.gov (NCT07264335). StuddyBuddy aggregates publicly available trial information.
